LLY

751.96

-3.18%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

AZN

67.28

-4.02%↓

LLY

751.96

-3.18%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

AZN

67.28

-4.02%↓

LLY

751.96

-3.18%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

AZN

67.28

-4.02%↓

LLY

751.96

-3.18%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

AZN

67.28

-4.02%↓

LLY

751.96

-3.18%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

AZN

67.28

-4.02%↓

Search

Johnson and Johnson

Aperta

SettoreSettore sanitario

155.56 -1.06

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

154.76

Massimo

157.02

Metriche Chiave

By Trading Economics

Entrata

7.6B

11B

Vendite

-627M

22B

P/E

Media del settore

17.241

54.379

EPS

2.77

Rendimento da dividendi

3.35

Margine di Profitto

50.24

Dipendenti

138,100

EBITDA

9.7B

16B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+8.56% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.35%

2.55%

Utili prossimi

16 lug 2025

Prossima data del Dividendo

10 giu 2025

Prossima data del' Ex Dividendo

27 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-4.3B

373B

Apertura precedente

156.62

Chiusura precedente

155.56

Notizie sul Sentiment di mercato

By Acuity

24%

76%

59 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Johnson and Johnson Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

15 apr 2025, 15:12 UTC

Utili

J&J Boosts Outlook Despite Incoming Tariff Costs -- Update

15 apr 2025, 10:35 UTC

Notizie principali
Utili

J&J Increases Outlook After Beating 1Q Expectations

7 mag 2025, 09:30 UTC

Notizie principali

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

4 mag 2025, 04:05 UTC

Acquisizioni, Fusioni, Takeovers

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

18 apr 2025, 11:00 UTC

Notizie principali

Johnson & Johnson Pivots Its AI Strategy -- WSJ

17 apr 2025, 20:34 UTC

Utili

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

17 apr 2025, 18:24 UTC

Utili

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

15 apr 2025, 19:06 UTC

Utili

These Stocks Are Moving the Most Today: Bank of America, Citigroup, Netflix, Boeing, Tesla, HPE, Applied Digital, and More -- Barrons.com

15 apr 2025, 18:52 UTC

Discorsi di Mercato
Utili

J&J's 1Q Performance Signals Positive Outlook for MedTech Sector -- Market Talk

15 apr 2025, 14:54 UTC

Utili

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

15 apr 2025, 13:19 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

15 apr 2025, 11:52 UTC

Utili

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

15 apr 2025, 11:14 UTC

Utili

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

15 apr 2025, 10:51 UTC

Utili

These Stocks Are Moving the Most Today: Boeing, Tesla, Bank of America, J&J, Netflix, Allegro MicroSystems, and More -- Barrons.com

15 apr 2025, 10:37 UTC

Notizie principali
Utili

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Rises. -- Barrons.com

15 apr 2025, 10:20 UTC

Utili

Johnson & Johnson Now Sees 2025 Operational Sales of $91.6B-$92.4B Vs. Prior Outlook $90.9B-$91.7B >JNJ

15 apr 2025, 10:20 UTC

Utili

Johnson & Johnson Backs 2025 Adj EPS $10.50-Adj EPS $10.70 >JNJ

15 apr 2025, 10:20 UTC

Utili

Johnson & Johnson Raises 2025 View To Sales $91B-$91.8B Vs Prior View $89.2B-$90B >JNJ

15 apr 2025, 10:20 UTC

Utili

Johnson & Johnson Now Sees 2025 Adjusted Operational EPS $10.50-$10.70 Vs Prior View $10.75-$10.95 >JNJ

15 apr 2025, 10:20 UTC

Utili

Johnson & Johnson: Including Tariff Costs, Dilution From Intra-Cellular Therapies Buy and Updated Forex, Maintain FY Adj EPS Outlook of 6.2% Growth at Mid-Point >JNJ

15 apr 2025, 10:20 UTC

Utili

Johnson & Johnson: Strong 1Q Operational Sales Growth Reinforces Our Confidence in 2025 Guidance >JNJ

15 apr 2025, 10:20 UTC

Utili

Johnson & Johnson 1Q Sales $21.89B >JNJ

15 apr 2025, 10:20 UTC

Utili

Johnson & Johnson: Increasing FY25 Operational Sales Guidance to Reflect Addition of Caplyta Following Completion of Intra-Cellular Therapies Acquisition >JNJ

15 apr 2025, 10:20 UTC

Utili

Johnson & Johnson 1Q Worldwide MedTech Sales $8.02B >JNJ

15 apr 2025, 10:20 UTC

Utili

Johnson & Johnson 1Q International Sales $9.59B >JNJ

15 apr 2025, 10:20 UTC

Utili

Johnson & Johnson 1Q Adj EPS $2.77 >JNJ

15 apr 2025, 10:20 UTC

Utili

Johnson & Johnson 1Q Orthopaedics Sales $2.24B >JNJ

15 apr 2025, 10:20 UTC

Utili

Johnson & Johnson: MedTech 1Q Operational Sales Growth Driven Primarily by Abiomed and Wound Closure Products, Partially Offset by Spine, Sports & Other >JNJ

15 apr 2025, 10:20 UTC

Utili

Johnson & Johnson Still Sees 2025 Adjusted Operational Sales Growth of 2.0%-3.0% >JNJ

15 apr 2025, 10:20 UTC

Utili

Johnson & Johnson: Innovative Medicine 1Q Sales Growth Driven in Part by Higher Sales of Darzalex and Spravato, Partially Offset by Falling Sales of Stelara >JNJ

Confronto tra pari

Modifica del prezzo

Johnson and Johnson Previsione

Obiettivo di Prezzo

By TipRanks

8.56% in crescita

Previsioni per 12 mesi

Media 170.77 USD  8.56%

Alto 185 USD

Basso 159 USD

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Johnson and Johnson - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

15 ratings

8

Acquista

7

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

154.93 / 155.895Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

59 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.